Dr. Fausto Leonardo Zaruma Torres

Researcher
University of Cuenca, Ecuador


Highest Degree
Ph.D. in Biotechnology from National Polytechnic Institute, Mexico

Share this Profile

Area of Interest:

Pharmacology and Toxicology
Pharmaceutical Sciences
Pharmacogenetics
Pharmacokinetics
Biochemistry

Selected Publications

  1. Quinones, L., A. Roco, J.P. Cayun, P. Escalante and C. Miranda et al., 2017. Farmacogenomica como herramienta fundamental para la medicina personalizada: aplicaciones in practica clinica. Rev. Med. Chile, 145: 483-500.
    CrossRef  |  Direct Link  |  

  2. Torres, F.Z., I.L. Asseff, A. Lima, A. Reyes-Espinoza and V. Loera-Castaneda, 2016. Genetic polymorphisms associated to folate transport as predictors of increased risk for acute lymphoblastic leukemia in Mexican children. Front. Pharmacol., 10.3389/fphar.2016.00238.
    CrossRef  |  Direct Link  |  

  3. Asseff, I.L., G.B. Gaucin, H.J. Olguin, J.A.G. Najera, A.T. Lopez, G.P. Guille and F.Z. Torres, 2016. Pharmacokinetics of ranitidine in preterm and term neonates with gastroesophageal reflux. BMC Pediatr., 10.1186/s12887-016-0630-x.
    CrossRef  |  Direct Link  |  

  4. Zaruma-Torres, F., I.L. Asseff, A.R. Espinoza, V.L. Castaneda and I.C. Hernandez et al., 2015. Association of ABCB1, ABCC5 and xanthine oxidase genetic polymorphisms with methotrexate adverse reactions in Mexican pediatric patients with All. De Gruyter, 10.1515/dmpt-2015-0011.
    CrossRef  |  Direct Link  |  

  5. Torres, F.L.Z., I.L. Asseff, A.R. Espinozal, V. Lopera-Castaneda, H.A. Reyes and M.C. Arias-Pelaez et al., 2015. Impact of genetic polymorphisms of the methotrexate metabolic pathway on the survival of Mexican children with All. Drug Metabol. Pers. Ther., 22: 177-187.
    CrossRef  |  Direct Link  |  

  6. Asseff, I.L., M.S. Macias, M.C. Velasco, O.C. Arreola, F.Z. Torres, M.D. Carrasco-Portugal and F.J. Flores-Murrieta, 2014. OCT1 and OCT2 polymorphisms and their association with metformin population pharmacokinetics in Mexican patients with type 2 diabetes. Clin. Pharmacol. Drug Dev., 3: 23-24.